Fracture risk in men with prostate cancer: A population-based study

Journal of Bone and Mineral Research

Volumn 26, Issue 8, 2011, Pages 1808-1815

  Melton III, L Joseph ^a,b   Lieber, Michael M ^a   Atkinson, Elizabeth J ^a   Achenbach, Sara J ^a   Zincke, Horst ^a   Therneau, Terry M ^a   Khosla, Sundeep ^b  

^a MAYO CLINIC   (United States)

^b Information Technology   (United States)

Author keywords

cohort study; epidemiology; fractures; population based; prostate cancer

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; COHORT ANALYSIS; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POPULATION RESEARCH; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; STANDARDIZED INCIDENCE RATIO;

AGED; FRACTURES, BONE; HUMANS; INCIDENCE; MALE; MINNESOTA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79960638216     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.405     Document Type: Article

References (45)

1. Khosla S, Melton LJ 3rd, Riggs BL,. Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab. 2002; 87: 1443-1450. (Pubitemid 34615219)
2. Melton LJ 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H,. Fracture risk following bilateral orchiectomy. J Urol. 2003; 169: 1747-1750. (Pubitemid 36443487)
3. Melton LJ 3rd, Alothman KI, Achenbach SJ, O'Fallon WM, Zincke H,. Decline in bilateral orchiectomy for prostate cancer in Olmsted County, Minnesota, 1956-2000. Mayo Clin Proc. 2001; 76: 1199-1203. (Pubitemid 33117013)
4. Higano CS,. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol. 2008; 5: 24-34.
5. Polascik TJ,. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis. 2008; 11: 13-19. (Pubitemid 351250325)
6. Bayoumi AM, Brown AD, Garber AM,. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000; 92: 1731-1739.
7. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
8. Ito K, Elkin EB, Girotra M, Morris MJ,. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010; 152: 621-629.
9. Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV,. Incidence and risk factors for low trauma fractures in men with prostate cancer. Bone. 2008; 43: 556-560.
10. Dickman PW, Adolfsson J, Astrom K, Steineck G,. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol. 2004; 172: 2208-2212. (Pubitemid 39507493)
11. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL,. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005; 23: 7897-7903. (Pubitemid 46657388)
12. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J,. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006; 175: 136-139; discussion 139. (Pubitemid 41797111)
13. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154-164. (Pubitemid 40096612)
14. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K,. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007; 100: 749-754. (Pubitemid 47360203)
15. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS,. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol. 2007; 178: 1423-1428. (Pubitemid 47376713)
16. Zhang Y, Kiel DP, Ellison RC, et al. Bone mass and the risk of prostate cancer: the Framingham Study. Am J Med. 2002; 113: 734-739. (Pubitemid 36044699)
17. Farhat GN, Taioli E, Cauley JA, et al. The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidemiol Biomarkers Prev. 2009; 18: 148-154.
18. Pfeilschifter J, Diel IJ,. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000; 18: 1570-1593. (Pubitemid 30205404)
19. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV,. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005; 20: 487-493. (Pubitemid 40293498)
20. Melton LJ 3rd., History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996; 71: 266-274.
21. Melton LJ 3rd., The threat to medical-records research. N Engl J Med. 1997; 337: 1466-1470.
22. U.S.D.H.H.S. Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Rockville, MD. 2004.
23. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd., Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7: 221-227.
24. Melton LJ 3rd, Crowson CS, O'Fallon WM,. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999; 9: 29-37. (Pubitemid 29086162)
25. Cox DR,. Some simple approximate tests for Poisson variates. Biometrika. 1953; 40: 354-360.
26. Kaplan EL, Meier P,. Non-parametic estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
27. Gooley TA, Leisenring W, Crowley J, Storer BE,. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695-706. (Pubitemid 29126745)
28. Kalbfleisch JD, Prentice RL,. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons, 1980.
29. Therneau TM, Grambsch PM,. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag, 2000.
30. Firth D,. Bias reduction of maximum likelihood estimates. Biometrika. 1993; 80: 27-38.
31. Lau YK, Lee E, Prior HJ, Lix LM, Metge CJ, Leslie WD,. Fracture risk in androgen deprivation therapy: a Canadian population based analysis. Can J Urol. 2009; 16: 4908-4914.
32. Psaty BM, Siscovick DS,. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010; 304: 897-898.
33. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S,. Bicalutamide 150mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004; 171: 2272-2276, quiz 2435. (Pubitemid 38625450)
34. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS,. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004; 22: 2546-2553. (Pubitemid 41103742)
35. Hernan MA,. The hazards of hazard ratios. Epidemiology. 2010; 21: 13-15.
36. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148: 197-213. (Pubitemid 351665507)
37. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS,. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008; 112: 2456-2466.
38. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19: 893-899. (Pubitemid 41103445)
39. Vestergaard P, Rejnmark L, Mosekilde L,. Methotrexate, azathioprine, cyclosporine, and risk of fracture. Calcif Tissue Int. 2006; 79: 69-75. (Pubitemid 44306163)
40. Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999; 159: 1750-1756. (Pubitemid 29379138)
41. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35: 375-382. (Pubitemid 38953182)
42. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005; 16: 1330-1338. (Pubitemid 41532085)
43. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001; 166: 1724-1728.
44. Curtis JR, Taylor AJ, Matthews RS, et al. " Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int. 2009; 20: 1969-1972.
45. Melton LJ 3rd, Kearns AE, Atkinson EJ, et al. Secular trends in hip fracture incidence and recurrence. Osteoporos Int. 2009; 20: 687-694.